# NEUROONE MEDICAL TECHNOLOGIES Corp: Form 10-Q for the period ended Mar 31, 2018

- Company: [NEUROONE MEDICAL TECHNOLOGIES Corp](/companies/nmtc.md) (CIK 1500198)
- Form: 10-Q
- Filed: 2018-05-16
- Accepted by EDGAR: May 16, 2018, 01:15 ET
- Period: 2018-03-31
- Accession: 0001213900-18-006399
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1500198/000121390018006399/f10q0318_neuroonemedical.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1500198/000121390018006399/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2018-01-01 to 2018-03-31 | $105.0k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2018-01-01 to 2018-03-31 | −$1.1m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2018-01-01 to 2018-03-31 | −$1.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-01-01 to 2018-03-31 | −$0.17 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months, 2018-01-01 to 2018-03-31 | −$591.3k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Current assets | at 2018-03-31 | $32.3k | us-gaap:AssetsCurrent |
| Total assets | at 2018-03-31 | $243.8k | us-gaap:Assets |
| Current liabilities | at 2018-03-31 | $5.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-03-31 | $6.6m | us-gaap:Liabilities |
| Short-term borrowings | at 2018-03-31 | $369.1k | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2018-03-31 | −$6.4m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1500198/000121390018006399/f10q0318_neuroonemedical.htm

Filed May 16, 2018.
Source: SEC EDGAR, the filing index for accession 0001213900-18-006399. Last ingested by Listed: Oct 24, 2026, 15:07 ET. No prices; not investment advice.
